CD4 and hepatocellular carcinoma: Therefore, in this study, we observed the proportion of CD4+CD25+CD127LowTregs in patients with primary hepatocellular carcinoma (HCC) before and after treatment and in healthy people, evaluate the clinical performance of CD4+CD25+CD127LowTregs in patients at high risk of HCC.